MedDataX Logo

Clinical Drug Trial in Healthy Male Subjects to Determine and Compare the Blood Concentrations of BI 144807 Following Administration as Oral Solution and Tablet Under Fasted and Fed Conditions

NCT ID: NCT01897597

Last Updated: 2013-09-06

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

31 participants

Study Classification

INTERVENTIONAL

Study Start Date

2013-07-31

Study Completion Date

2013-09-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this trial is to investigate the relative bioavailability of a BI 144807 tablet formulation compared to the oral solution formulation after single dose administration (intermediate and high dose) under fasted conditions. Further objectives are to assess whether and to what extent food affects single dose pharmacokinetics of BI 144807 administered as tablet, and to compare the relative bioavailability of two different tablet formulations.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Relative Bioavailability of BI 1467335 Tablet and Oral Solution, and Food Effect on Tablet in Healthy Male Subjects

NCT02999191

Healthy Volunteers
COMPLETED PHASE1

Bioavailability and Pharmacokinetics of BI 10773 Tablet in Healthy Male Volunteers

NCT02172209

Healthy
COMPLETED PHASE1

A Study to Test How BI 1819479 is Taken up and Processed by the Body

NCT07065617

Healthy
TERMINATED PHASE1

Single Rising Oral Doses of BI 207127 NA as Powder in the Bottle in Healthy Male Subjects

NCT02182388

Healthy
COMPLETED PHASE1

A Study in Healthy Men to Test How Different Doses of BI 1584862 Are Tolerated and How BI 1584862 is Taken up in the Body With or Without Food

NCT05520827

Healthy
COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Healthy

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

BI 144807 PfoS Treatment A

intermediate dose of BI 144807

Group Type EXPERIMENTAL

BI 144807 intermediate dose

Intervention Type DRUG

oral solution

BI 144807 PfoS Treatment C

high dose of BI 144807

Group Type EXPERIMENTAL

BI 144807 high dose

Intervention Type DRUG

oral solution

BI 144807 Tab Treatment B

intermediate dose of BI 144807

Group Type EXPERIMENTAL

BI 144807 intermediate dose

Intervention Type DRUG

tablet

BI 144807 Tab Treatment D

high dose of BI 144807

Group Type EXPERIMENTAL

BI 144807 high dose

Intervention Type DRUG

tablet

BI 144807 Tab Treatment E

intermediate dose of BI 144807, fasted

Group Type EXPERIMENTAL

BI 144807 intermediate dose

Intervention Type DRUG

tablet

BI 144807 Tab Treatment F

intermediate dose of BI 144807, fed

Group Type EXPERIMENTAL

BI 144807 intermediate dose

Intervention Type DRUG

tablet

BI 144807 Tab Treatment G

intermediate dose of BI 144807, fasted

Group Type EXPERIMENTAL

BI 144807 intermediate dose

Intervention Type DRUG

tablet

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

BI 144807 high dose

oral solution

Intervention Type DRUG

BI 144807 intermediate dose

tablet

Intervention Type DRUG

BI 144807 intermediate dose

tablet

Intervention Type DRUG

BI 144807 intermediate dose

tablet

Intervention Type DRUG

BI 144807 intermediate dose

tablet

Intervention Type DRUG

BI 144807 intermediate dose

oral solution

Intervention Type DRUG

BI 144807 high dose

tablet

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

\- Healthy male subjects

Exclusion Criteria

\- Any relevant deviation from healthy condition
Minimum Eligible Age

18 Years

Maximum Eligible Age

55 Years

Eligible Sex

MALE

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Boehringer Ingelheim

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Boehringer Ingelheim

Role: STUDY_CHAIR

Boehringer Ingelheim

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

1313.9.1 Boehringer Ingelheim Investigational Site

Biberach, , Germany

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Germany

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2013-000258-23

Identifier Type: EUDRACT_NUMBER

Identifier Source: secondary_id

1313.9

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

To Assess Safety, Tolerability and Pharmacokinetics of BI 730357 in Healthy Male Volunteers
NCT03004404 COMPLETED PHASE1
Safety, Tolerability, Pharmacokinetics of Single Rising Oral Doses of BI 1181181 in Healthy Male Volunteers, Including Investigation of the Effect of Food on the Bioavailability of BI 1181181
NCT02044406 COMPLETED PHASE1
Metabolism and Pharmacokinetics of [14C]-BI 44370 BS Administered as an Oral Solution in Healthy Male Volunteers
NCT02215772 COMPLETED PHASE1
Safety, Tolerability, Pharmacokinetics and Early Pharmacodynamics of Single Rising Oral Doses of BI 1021958 Tablets in Healthy Male Volunteers
NCT01541488 COMPLETED PHASE1
A Study in Healthy Men to Test if Taking Different Formulations of BI 1358894 With or Without Food Influences the Amount of BI 1358894 in the Blood
NCT03892616 COMPLETED PHASE1
A Study in Healthy Men to Find Out How Different Doses of BI 3009947 Are Tolerated and How Different Formulations or Food Influence How BI 3009947 is Taken up Into the Blood
NCT07250048 RECRUITING PHASE1
This Study Tests How Different Doses of BI 690517 Are Taken up in the Body of Healthy Men. The Study Also Looks at How Food Influences the Amount of BI 690517 in the Blood
NCT03100916 COMPLETED PHASE1
Relative Bioavailability of BI 207127 Trial Formulation II Prototypes Versus BI 207127 Trial Formulation I in Healthy Volunteers
NCT02182414 COMPLETED PHASE1
A Study in Healthy Men to Test How Well Different Doses of BI 1569912 Are Tolerated and How Food Influences the Amount of BI 1569912 in the Blood
NCT04445090 TERMINATED PHASE1
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Ascending Oral Doses and Effect of Food on the Bioavailability of BI 1060469
NCT01971502 COMPLETED PHASE1
A Study in Healthy Men to Test How Different Doses of BI 1815368 Are Tolerated and How BI 1815368 is Taken up in the Body With or Without Food
NCT05337592 COMPLETED PHASE1
Bioavailability of 3 Different Formulations of BI 207127 in Healthy Male Volunteers
NCT01535638 COMPLETED PHASE1
Relative Bioavailability of a BI 187004 Tablet Formulation in Comparison With an Oral Solution and the Influence of Food on the Tablet Formulation in Healthy Volunteers
NCT02161432 COMPLETED PHASE1
A Study in Healthy Men to Test How Well Different Doses of BI 1819479 Are Tolerated and Taken up by the Body With or Without Food
NCT04801693 COMPLETED PHASE1
Relative Oral Bioavailability of BI 44847 as Suspension Compared to Tablet and the Influence of Food Anf of BI 44847 as Solution Compared to Tablet in Healthy Male Volunteers
NCT02211937 COMPLETED PHASE1
To Assess Safety, Tolerability and Pharmacokinetics of BI 416970 in Healthy Male Volunteers
NCT02093819 COMPLETED PHASE1
Safety, Tolerability and Pharmacokinetics of BI 44370 TA Oral Drinking Solution in Healthy Male Volunteers
NCT02215018 COMPLETED PHASE1
A Study in Healthy Men to Test How BI 1015550 is Taken up and Handled by the Body
NCT05707403 COMPLETED PHASE1
Bioavailability and Pharmacokinetics of BI 135585 XX Administered as Tablet With and Without Food
NCT01286571 COMPLETED PHASE1
Safety, Tolerability and Pharmacokinetics of Single Rising Oral Doses of BI 113823 Powder in Bottle (PiB) and Tablet in Healthy Male Volunteers
NCT02259972 COMPLETED PHASE1
Bioavailability of BI 44370 TA Drinking Solution or Tablets With and Without a High Fat Meal in Healthy Male and Female Volunteers
NCT02215746 COMPLETED PHASE1
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Rising Oral Doses of BI 639667
NCT02133482 WITHDRAWN PHASE1
This Study in Healthy Men Tests How Different Doses of BI 894416 Are Taken up in the Body and How Well BI 894416 is Tolerated
NCT03315936 COMPLETED PHASE1
A Study in Healthy Men and Women to Test How BI 3000202 is Taken up and Processed by the Body
NCT07273474 RECRUITING PHASE1
BI 10773 Administered as Oral Solution to Healthy Male Volunteers
NCT02172274 COMPLETED PHASE1